Laserfiche WebLink
Docusign Envelope ID: D1EF72EC-17B5-459A-93D1-E82ABEFBOE5C <br />A-2025-161 <br />o:CAo (0) OCT 2025 <br />Laur0.Ros5ini/ <br />powiOl Quintanp 02) <br />EXHIBIT K <br />Secondary Manufacturers' Combined Subdivision Participation and Release Form <br />("Combined Participation Form") <br />Governmental Entity: Santa Ana city <br />State: CA <br />Authorized Official: Alvaro Nunez <br />Address 1: 20 Civic Center Plaza, M-31 <br />Address 2: P.O. Box 1988 <br />City, State, Zip: Santa Ana, CA 92702 <br />Phone: 714-647-5220 <br />Email: ANufiez@santa-ana.org <br />The governmental entity identified above ("Governmental Entity"), in order to obtain and <br />in consideration for the benefits provided to the Governmental Entity pursuant to each of the <br />settlements which are listed in paragraph 1 below (each a "Secondary Manufacturer's Settlement" <br />and collectively, "the Secondary Manufacturers' Settlements"), and acting through the <br />undersigned authorized official, hereby elects to participate in each of the Secondary <br />Manufacturers' Settlements, release all Released Claims against all Released Entities in each of the <br />Secondary Manufacturers' Settlements, and agrees as follows. <br />1. The Participating Entity hereby elects to participate in each of the following Secondary <br />Manufacturers' Settlements as a Participating Entity: <br />a. Settlement Agreement for Alvogen, Inc. dated April 4, 2025. <br />b. Settlement Agreement for Apotex Corp. dated April 4, 2025. <br />C. Settlement Agreement for Amneal Pharmaceuticals LLC dated April 4, 2025. <br />d. Settlement Agreement for Hikma Pharmaceuticals USA Inc. dated April 4, 2025. <br />e. Settlement Agreement for Indivior Inc. dated April 4, 2025. <br />f. Settlement Agreement for Viatris Inc. ("Mylan") dated April 4, 2025. <br />g. Settlement Agreement for Sun Pharmaceutical Industries, Inc. dated April 4, 2025. <br />h. Settlement Agreement for Zydus Pharmaceuticals (USA) Inc. dated April 4, 2025. <br />2. The Governmental Entity is aware of and has reviewed each of the Secondary <br />Manufacturers' Settlements, understands that all capitalized terms not defined in this <br />Combined Participation Form have the meanings defined in each of the Secondary <br />Manufacturers' Settlements, and agrees that by executing this Combined Participation <br />Form, the Governmental Entity elects to participate in each of the Secondary <br />Manufacturers' Settlements and become a Participating Subdivision as provided in each of <br />the Secondary Manufacturers' Settlements. <br />3. The Governmental Entity shall promptly, and in any event no later than 14 days after the <br />Reference Date and prior to the filing of the Consent Judgment, dismiss with prejudice any <br />Released Claims that it has filed against any Released Entity in each of the Secondary <br />Manufacturers' Settlements. With respect to any Released Claims pending in In re <br />National Prescription Opiate Litigation, MDL No. 2804, the Governmental Entity <br />